Miclescu Adriana, Basu Samar, Wiklund Lars
Department of Surgical Sciences/Anaesthesiology, Faculty of Medicine, Uppsala University, S-751 85 Uppsala, Sweden.
Resuscitation. 2007 Oct;75(1):88-97. doi: 10.1016/j.resuscitation.2007.03.014. Epub 2007 May 4.
Methylene blue (MB) administered with a hypertonic-hyperoncotic solution reduces the myocardial and cerebral damage due to ischaemia and reperfusion injury after experimental cardiac arrest and also increases short-term survival. As MB precipitates in hypertonic sodium chloride, an alternative mixture of methylene blue in hypertonic sodium lactate (MBL) was developed and investigated during and after cardiopulmonary resuscitation (CPR).
Using an experimental pig model of cardiac arrest (12 min cardiac arrest and 8 min CPR) the cardio-cerebral and metabolic effects of MBL (n=10), MB in normal saline (MBS; n=10) or in hypertonic saline dextran (MBHSD; n=10) were compared. Haemodynamic variables and cerebral cortical blood flow (CCBF) were recorded. Biochemical markers of cerebral oxidative injury (8-iso-PGF2alpha), inflammation (15-keto-dihydro-PGF2alpha), and neuronal damage (protein S-100beta) were measured in blood from the sagittal sinus, whereas markers of myocardial injury, electrolytes, and lactate were measured in arterial plasma.
There were no differences between groups in survival, or in biochemical markers of cerebral injury. In contrast, the MBS group exhibited not only increased CKMB (P<0.001) and troponin I in comparison with MBHSD (P=0.019) and MBL (P=0.037), but also greater pulmonary capillary wedge pressure 120 min after return of spontaneous circulation (ROSC). Lactate administration had an alkalinizing effect started 120 min after ROSC.
Methylene blue in hypertonic sodium lactate may be used against reperfusion injury during experimental cardiac arrest, having similar effects as MB with hypertonic saline-dextran, but in addition better myocardial protection than MB with normal saline. The neuroprotective effects did not differ.
亚甲蓝(MB)与高渗 - 高胶体渗透压溶液联合应用可减轻实验性心脏骤停后缺血再灌注损伤所致的心肌和脑损伤,还能提高短期生存率。由于MB在高渗氯化钠中会沉淀,因此研发了一种高渗乳酸钠中的亚甲蓝替代混合物(MBL),并在心肺复苏(CPR)期间及之后进行了研究。
使用心脏骤停的实验猪模型(心脏骤停12分钟,CPR 8分钟),比较了MBL(n = 10)、生理盐水亚甲蓝(MBS;n = 10)或高渗盐水右旋糖酐亚甲蓝(MBHSD;n = 10)对心脑及代谢的影响。记录血流动力学变量和脑皮质血流量(CCBF)。在矢状窦血中测量脑氧化损伤(8 - 异前列腺素F2α)、炎症(15 - 酮 - 二氢 - 前列腺素F2α)和神经元损伤(蛋白S - 100β)的生化标志物,而在动脉血浆中测量心肌损伤、电解质和乳酸的标志物。
各组在生存率或脑损伤生化标志物方面无差异。相比之下,MBS组不仅与MBHSD(P = 0.019)和MBL(P = 0.037)相比,肌酸激酶同工酶(CKMB)升高(P < 0.001)且肌钙蛋白I升高,而且在自主循环恢复(ROSC)后120分钟时肺毛细血管楔压更高。乳酸给药在ROSC后120分钟开始产生碱化作用。
高渗乳酸钠中的亚甲蓝可用于对抗实验性心脏骤停期间的再灌注损伤,其效果与高渗盐水 - 右旋糖酐中的MB相似,但此外对心肌的保护作用优于生理盐水亚甲蓝。神经保护作用无差异。